ClinicalTrials.gg
RecruitingNCT06889974TENDERSUpdated Jan 9, 2026

Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome

An observational study in Renal Replacement Therapy for Acute Kidney Injury in ICU, sponsored by University Hospital, Bordeaux. Recruiting at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by University Hospital, Bordeaux · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 154 studies in Acute Kidney Injury with a site in France — 31 open to participants now, 35 under way, 4 of them phase 3. Acute Kidney Injury · France.

Planned enrollment
13th of 76
800 · median 190
Started
2025
with 8 others
Observational
76 of 154
13 open now
Primary completion
2027-07
later than 23 of 34 live
Registered
145th of 154
by date
Lead sponsor
6 of 154
University Hospital, Bordeaux

Among the 154 studies in Acute Kidney Injury with a site in France, this one is the 13th largest by planned enrollment of the 76 observational ones that give a count, is one of 9 that started in 2025, is one of 76 observational ones, reaches primary completion later than 23 of the 34 other live ones, and was the 145th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

31 of the 154 studies in Acute Kidney Injury with a site in France are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Acute Kidney Injury with a site in France, or all of them as a file.
02

Study summary

The TENDERS study aims to evaluate the impact of the timing of renal replacement therapy (RRT) initiation on outcomes in patients with tumor lysis syndrome (TLS) and associated acute kidney injury (AKI). The study will compare early versus delayed RRT initiation, examining the effect on renal function at 30 days post-treatment.

Read the detailed description

Tumor lysis syndrome (TLS) is a common and life-threatening complication in patients with hematologic malignancies, characterized by severe metabolic imbalances due to rapid tumor cell destruction. This syndrome frequently leads to acute kidney injury (AKI), requiring renal replacement therapy (RRT) in about 50% of cases. Despite its clinical significance, there is a lack of consensus on the optimal timing of RRT initiation in TLS-related AKI. Studies in other forms of AKI suggest no difference in outcomes between early and delayed RRT initiation, but these results are not directly applicable to TLS patients. This study seeks to fill this gap by analyzing the timing and outcomes of RRT initiation in TLS patients. The retrospective study will collect data from multiple intensive care units (ICUs) across France. Procedure: The study will retrospectively analyze patient data from 2013 to 2023, comparing early vs. delayed RRT initiation. Follow-up: Data on renal function, RRT usage, and mortality will be collected 30 days and one year after ICU admission.

03

Conditions studied

  • Renal Replacement Therapy for Acute Kidney Injury in ICU

Browse trials for

Keywords

  • tumoral lysis syndrome
  • acute kidney injury
  • renal replacement therapy, timing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This is a retrospective, multicenter cohort study conducted across several intensive care units (ICUs) in France. Data will be collected retrospectively from patient records and analyzed to assess the impact of early versus delayed RRT initiation on clinical outcomes in patients with TLS-induced AKI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18 years.
  • Hospitalized in the ICU between January 1, 2013, and December 31, 2023.
  • Diagnosed with a hematologic or solid tumor requiring chemotherapy.
  • Diagnosed with TLS based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation.

Exclusion criteria

Exclusion Criteria:

  • Patient or family opposition to data collection for research purposes.
  • Incomplete medical records that preclude data extraction.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with early initiation of renal replacement therapy (RRT)

    Patients with early initiation of RRT, RRT within 24 hours of acute kidney injury (AKI) diagnosis.

  • Patients with delayed initiation of RRT

    Patients with delayed initiation of RRT, RRT initiated only after urgent clinical indications arise, such as severe hyperkalemia or metabolic acidosis.

06

What researchers measure

Primary outcomes

  1. Renal dysfunction at ICU discharge

    The primary outcome is renal dysfunction at ICU discharge, defined as a ≥25% increase in serum creatinine from baseline, assessed at the time of ICU discharge.

    Time frame: From baseline to up to 30 days .

Secondary outcomes

  1. Incidence of AKI

    Incidence of AKI related to Tumor lysis syndrome (TLS), assessed at ICU admission.

    Time frame: At baseline

  2. Use of RRT for TLS-related AKI

    Use of RRT for TLS-related AKI, assessed during ICU stay.

    Time frame: From baseline to up to 30 days.

  3. Renal recovery

    90-day renal recovery, assessed at 90 days post-admission.

    Time frame: At 90 days after baseline

  4. Long-term renal function

    Long-term renal function is assessed by creatinine at one year

    Time frame: 12 months after baseline

  5. Mortality at 30 days

    Mortality rate at 30 days.

    Time frame: 30 days after baseline

  6. Mortality at 12 months

    Mortality rate 12 months post ICU admission

    Time frame: 12 months after baseline

  7. Long-term renal function

    Long-term renal function is assessed by glomerular filtration rate at one year

    Time frame: 12 months after baseline

07

Study locations

8 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 21, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06889974
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Jul 1, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jan 9, 2026

Study contacts

Arthur ORIEUX
Contact
arthur.orieux@chu-bordeaux.fr
05 56 70 56 79 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion